147
CD/UC
Bortlik et al. [83]
CD: 61UC: 17
Prospective observational (77% of CD and 59% of UC with concomitant IMM)
CD: 18% (0.5 year), 41% (1 year), 49% (2 years)
Non-colonic location for CD, previous anti-TNF-
α^
treatment, previous surgery
Type of anti-TNF-
α agent,
smoking status, disease behavior, corticosteroid therapy within 1 year before biologics withdrawal, concomitant IMM, CRP level, fecal calprotectin, anti-TNF-
α trough levels at
the time of anti-TNF-
α^
withdrawal
82%
UC: 23% (0.6 year), 23% (1 year), 36% (2 years)
Dai et al. [
49
]
CD: 109
Prospective observational
CD: 21% (1 year)
Nil
Clinical remission, mucosal healing, gender, disease duration, smoking status, history of appendicectomy, location, behavior, extraintestinal manifestations, previous surgery, previous biological therapy, CRP level, effect of induction therapy
CD: 78.3%
UC: 107
(31% concomitant IMM)
UC: 14% (1 year)
UC: 66.7%
Hlavaty et al. [^84
]
CD:17
Prospective observational
Cohorts with deep remission, 18% (0.5 year), 27% (1 year)
Male
Type of IBD, age, disease duration, CD location, behavior, smoking status, previous surgery, type and duration of anti-TNF-
α agent,
concomitant azathioprine, fecal calprotectin, CRP, hemoglobin
100%
(36% with concomitant IMM for cohorts in clinical remission)(64% with concomitant IMM for cohorts in deep remission)
UC: 5
Cohorts with clinical remission, 18% (0.5 year), 27% (1 year)
(continued)
10 Cessation offlBiologics: Can It BeflDone?